Cargando…

Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis

It remains unclear which adjunctive drug for Parkinson’s disease (PD) in combination with levodopa is more effective, tolerable, and safe. We aimed to compare the efficacy, tolerability, and safety among anti-PD drugs from several classes in patients with fluctuating PD who received levodopa through...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sako, Wataru, Kogo, Yuki, Koebis, Michinori, Kita, Yoshiaki, Yamakage, Hajime, Ishida, Takayuki, Hattori, Nobutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584871/ https://www.ncbi.nlm.nih.gov/pubmed/37853009 http://dx.doi.org/10.1038/s41531-023-00589-8

Ejemplares similares

The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Correction: Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022)

Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease
por: Virmani, Tuhin, et al.
Publicado: (2016)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
por: Annus, Ádám, et al.
Publicado: (2017)

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Kano, Osamu, et al.
Publicado: (2022)

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Kwak, Nayoung, et al.
Publicado: (2022)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts
por: Yasuda, Hajime, et al.
Publicado: (2022)

Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study
por: Murata, Miho, et al.
Publicado: (2018)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Mood fluctuations in Parkinson’s disease: a pilot study comparing the effects of intravenous and oral levodopa administration
por: Richard, Irene Hegeman, et al.
Publicado: (2005)

Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
por: Noui, Yassine, et al.
Publicado: (2021)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis
por: Wang, Yan, et al.
Publicado: (2021)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
por: Nomoto, Masahiro, et al.
Publicado: (2018)

The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson’s Disease with Motor Fluctuations
por: Wei, Qianqian, et al.
Publicado: (2022)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Controlled-Release Levodopa for the Treatment of Rapid Motor Fluctuations in Parkinson's Disease Subjects with Subthalamic Nucleus Deep Brain Stimulation
por: Onder, Halil, et al.
Publicado: (2023)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Prevalence of and factors associated with acute withdrawal symptoms after 24 weeks of eszopiclone treatment in patients with chronic insomnia: a prospective, interventional study
por: Inoue, Yuichi, et al.
Publicado: (2021)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
por: Marzinzik, Frank, et al.
Publicado: (2011)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bur2vls4dg5f4on2crkj13do73